South Africa’s GLP-1 market has entered a new phase: Sun Pharma’s local subsidiary Ranbaxy has launched Semagard, the country’s first generic semaglutide injection, at a price roughly 18.5% below Novo Nordisk’s brand-name Ozempic. The launch follows the March 2026 expiry of semaglutide’s patent protection in several markets and lands amid an intensifying regulatory battle against South Africa’s black market for compounded and counterfeit weight-loss jabs.
The first generic GLP-1 on SA shelves
Semagard is the first of what health journalists and regulators expect to be a wave of generic GLP-1 medicines reaching South African pharmacies over the next 12–18 months. Sun Pharma’s entry follows the South African Health Products Regulatory Authority’s (SAHPRA) approval of the company’s generic semaglutide earlier in 2026, which made South Africa the second market after India to register a generic version of the drug.
Pricing still out of reach for most
Despite the price cut, affordability remains a central concern. Branded GLP-1 medicines in South Africa typically cost between R3,000 and R10,000 a month, and Semagard’s roughly 18.5% discount narrows that gap only modestly. Researchers cited in this week’s coverage estimate that semaglutide could theoretically be manufactured for as little as R100–R200 a month, with the injection pen delivery device — not the active ingredient — responsible for much of the retail price. Novo Nordisk’s own lower-cost variant, Extensior, launched in July at around a 15% discount to Ozempic, meaning South African patients now have two discounted originator-adjacent options alongside the new generic.
More generics in SAHPRA’s pipeline
SAHPRA is currently reviewing roughly 13 additional generic semaglutide applications and 18 for liraglutide, according to this week’s reporting, suggesting further price competition is likely as more manufacturers clear the regulatory pipeline. SAHPRA’s leadership has also disclosed that the regulator’s whistle-blowing platform continues to receive two to three complaints a week about unregistered GLP-1 products being advertised on social media — a sign that regulatory approvals alone have not resolved the underlying demand-and-supply mismatch driving illegal trade.
The black market keeps operating
Multiple outlets covering the Semagard launch this week returned to the risks posed by illegal compounding pharmacies and smuggled product. Compounded GLP-1s manufactured outside proper oversight have been linked to contamination, incorrect dosing and undisclosed ingredients, with at least one previously raided compounding operation reported to have supplied prescriptions at a scale far beyond legitimate individual patient compounding. Stavros Nicolaou of Aspen Pharmacare, quoted in this week’s coverage, warned that with black-market product “you cannot determine…whether the product is being made under good manufacturing conditions,” a risk that has previously landed patients in intensive care.
A public health backdrop of rising obesity
The reporting also situates the generic launch within South Africa’s broader obesity trend: female obesity rates rose from around 30% to 43% between 1998 and 2017, and clinicians note that some patients are also using GLP-1s to manage weight gain linked to antiretroviral HIV treatment. With roughly 84% of South Africans dependent on the public healthcare system — where GLP-1 coverage remains limited largely to select diabetes cases — medical aid and public-sector access remain the key unresolved questions even as branded and generic prices edge down.
What this means for patients
- A generic semaglutide option (Semagard) is now legally available in South Africa at a discount to Ozempic, but it is still a prescription medicine — it should only be sourced through a registered pharmacy with a valid prescription.
- Price relief so far is incremental (around 15–18.5% below the originator), not the dramatic drop some patients may be expecting; medicine costs are likely to keep falling gradually as more generics clear SAHPRA review.
- Products bought via social media, informal WhatsApp sellers or unregistered online suppliers carry real safety risks, including contamination and incorrect dosing, and are not covered by the same manufacturing oversight as registered medicines.
- Patients on medical aid should confirm with their scheme whether Semagard or other GLP-1 medicines are covered, as reimbursement for weight-loss (rather than diabetes) indications remains inconsistent across schemes.
- Anyone unsure whether a GLP-1 product they have been offered is legitimate can report suspected illegal sales to SAHPRA’s whistle-blowing platform.
This article is for general information purposes only and does not constitute medical advice. Always consult a registered healthcare professional before starting, stopping or switching any GLP-1 medicine, and source prescription medicines only from licensed South African pharmacies.
Sources
- The first generic weight-loss drug hit SA in August — with many expected to follow. Will it be enough to kill the black market? — Bhekisisa, 24 August 2026
- The first generic weight loss drug has hit SA — will it be enough to kill the black market? — Daily Maverick, 24 August 2026
- Generic weight loss drugs are in SA. Will they kill the black market? — News24, 24 August 2026
- The First Generic Weight Loss Drug Hit South Africa In August — With Many Expected To Follow — allAfrica, 24 August 2026
- The first generic weight-loss drug hit SA in August — with many expected to follow — Mail & Guardian, 25 August 2026
- The first wave of generic weight-loss drugs hit SA in August. Will it be enough to kill the black market? — TimesLIVE, 25 August 2026